Lumos Pharma, Inc.
LUMO · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.33 | 0.02 | -0.05 | -0.05 |
| FCF Yield | -15.53% | -34.80% | -56.02% | -79.95% |
| EV / EBITDA | -2.47 | -1.02 | -0.59 | 0.27 |
| Quality | ||||
| ROIC | -68.92% | -45.94% | -45.16% | -29.28% |
| Gross Margin | 100.00% | 99.59% | 98.79% | 97.82% |
| Cash Conversion Ratio | 0.67 | 0.84 | 1.23 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.45% | 26.50% | 64.75% | 107.37% |
| Free Cash Flow Growth | 21.54% | 50.52% | 37.40% | -1,330.42% |
| Safety | ||||
| Net Debt / EBITDA | 1.75 | 1.32 | 1.53 | 2.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 21.57 | -15,134.02 | -25,506.27 | -4,427.12 |